TELO TELOMIR PHARMA
TELOMIR PHARMA (TELO) is expected to report earnings on November 12, 2026, before the market open.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About TELOMIR PHARMA
Telomir Pharmaceuticals Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. Telomir Pharmaceuticals Inc. is based in BALTIMORE.
Charts powered in part by Lightweight Charts™ by TradingView.